Here are the The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
The real real luxury consignment, the real slim shady lyrics, the real world safety profile of tirzepatide vs semaglutide, math in the real world, the real world safety profile of tirzepatide dangers.
The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Purpose: Randomized controlled trials with tirzepatide (TZP) displayed unprecedented glucose and body weight lowering efficacy in individuals with type 2 diabetes and/or obesity and a safety profile similar to that of glucagon-like peptide-1 receptor agonists (GLP-1RA), mainly characterized by gastrointestinal (GI) adverse events (AE). Concerns on diabetic retinopathy, pancreato-biliary disorders, and medullary thyroid cancer were also addressed. We aimed to investigate whether the same safety issues emerged from the FDA Adverse Event Reporting System (FAERS) post-marketing surveillance database.
Methods: OpenVigil 2.1-MedDRA-v24 and AERSMine (data 2004Q1-2023Q3) were used to query the FAERS database. Reports of GI AE, diabetic retinopathy, pancreato-biliary disorders, and medullary thyroid cancer were investigated. The analysis was then filtered for age, gender, and designation as primary suspect. AE occurrence with TZP was compared to insulin, sodium -glucose cotransporter-2 inhibitors, metformin, and GLP-1RA.
Results: Disproportionate reporting of GI [i.e., nausea (ROR 4.01, 95% CI 3.85–4.19)] and pancreato-biliary disorders [i.e., pancreatitis (ROR 3.63, 95% CI 3.15–4.19)], diabetic retinopathy (ROR 4.14, 95% CI 2.34–7.30), and medullary thyroid cancer (ROR 13.67, 95% CI 4.35–42.96) was detected. TZP exhibited a similar risk of GI AE and medullary thyroid cancer and a lower risk of most pancreato-biliary AE and diabetic retinopathy vs. GLP-1RA. Conclusions: TZP was associated with an increased risk of specific AE. However, its safety profile was similar to that of GLP-1RA, without increased risk of pancreato-biliary AE, diabetic retinopathy, and medullary thyroid cancer. © The Author(s) 2024.
Authors : Caruso I.; Di Gioia L.; Di Molfetta S.; Caporusso M.; Cignarelli A.; Sorice G.P.; Laviola L.; Giorgino F.
Source : Springer Science and Business Media Deutschland GmbH
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1007/s40618-024-02441-z |
| ISSN | 03914097 |
| Volume | 47 |
You can download the article here
If You have any problem, contact us here